RLYB
Rallybio Corp

615
Mkt Cap
$46.92M
Volume
145,810.00
52W High
$11.49
52W Low
$1.76
PE Ratio
-5.27
RLYB Fundamentals
Price
$8.87
Prev Close
$9.09
Open
$9.00
50D MA
$6.69
Beta
1.37
Avg. Volume
63,498.92
EPS (Annual)
-$1.59
P/B
0.81
Rev/Employee
$61,285.71
$23.66
Loading...
Loading...
News
all
press releases
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 6, 2026 Insiders may stand to receive...
PR Newswire·16d ago
News Placeholder
More News
News Placeholder
Rallybio (RLYB) Expected to Announce Earnings on Thursday
Rallybio (NASDAQ:RLYB) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and...
Business Wire·18d ago
News Placeholder
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 2, 2026 Insiders may stand to receive...
PR Newswire·20d ago
News Placeholder
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio...
Business Wire·20d ago
News Placeholder
Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of "Reduce" by Brokerages
Rallybio Corporation (NASDAQ:RLYB - Get Free Report) has been assigned a consensus rating of "Reduce" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One...
MarketBeat·20d ago
News Placeholder
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Rallybio Corporation (Nasdaq: RLYB) ('Rallybio') and Candid Therapeutics, Inc. ('Candid'), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ('TCE...
Business Wire·20d ago
News Placeholder
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good safety and Phase 2 plans ahead.read more...
Benzinga·1mo ago
News Placeholder
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1mo ago
News Placeholder
Rallybio Announces Reverse Stock Split of Common Stock
Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybios Amended and...
Business Wire·2mo ago
<
1
2
...
>

Latest RLYB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.